Novel Oral Treatment Reduced Liver Fat in MASH

Novel oral drugs HU6 and DR10624 have shown significant promise in reducing liver fat and improving liver health in adults with MASH and hypertriglyceridemia, filling a critical treatment gap. This breakthrough offers new hope for millions worldwide suffering from MASH, highlighting a potential shift in the management of this condition.